Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Aura Biosciences raises $21M series B

March 6, 2015 2:27 AM UTC

Aura Biosciences Inc. (Cambridge, Mass.) raised $21 million in a series B round led by Advent Life Sciences. New investors Chiesi Ventures, Ysios Capital and Alexandria Venture Investments also participated, as did existing investors Li-Cor Biosciences (Lincoln, Neb.) and Henri Termeer, former president and CEO of Genzyme Corp.

Aura expects to start a clinical trial by YE15 of lead candidate AU011 to treat rare ocular cancers. AU011 consists of viral nanoparticles that target tumor cells conjugated to Li-Cor's IRDye 700DX, a laser-activated cytotoxin (see BioCentury Nov. 14, 2011). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article